1 |
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
DOI
|
2 |
Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7.
DOI
|
3 |
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.
DOI
|
4 |
Erdmann E, Wilcox R. Pioglitazone and mechanisms of CV protection. QJM 2010;103:213-28.
DOI
|
5 |
Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012;18:1519-30.
DOI
|
6 |
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
DOI
|
7 |
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
DOI
|
8 |
Choo EH, Han EJ, Kim CJ, et al. Effect of pioglitazone in combination with moderate dose statin on atherosclerotic inflammation: randomized controlled clinical trial using serial FDG-PET/CT. Korean Circ J 2018;48:591-601.
DOI
|
9 |
Lazich I, Sarafidis P, de Guzman E, Patel A, Oliva R, Bakris G. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab 2012;14:181-6.
DOI
|
10 |
Lawal I, Sathekge M. F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection. Br Med Bull 2016;120:55-74.
DOI
|